CTMX vs KIM · rev $11.7M vs P/E 27, rev $1.11B
CytomX Therapeutics Inc (CTMX) versus Kimco Realty Corporation (KIM) — a side-by-side from cached financials, not a winner call.
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
Kimco Realty Corporation (KIM) is a reit - retail company listed on US.
Latest reported CTMX revenue for 2026-06-30 was $11.7M. Net income was -$38.9M. Revenue was up 13.8% from 2026-03-31 to 2026-06-30. CTMX currently screens at market cap $653.1M.
Latest reported KIM revenue for 2026-06-30 was $1.11B. Net income was $318.2M. Revenue was up 98.7% from 2026-03-31 to 2026-06-30. KIM currently screens at market cap $16.03B and trailing P/E 27.3.
CTMX currently screens at market cap $653.1M. KIM currently screens at market cap $16.03B and trailing P/E 27.3.
Not investment advice. Open the CTMX and KIM stock pages for the full models.
Not investment advice.